Literature DB >> 1334417

Binding of botulinum neurotoxin to pure cholinergic nerve terminals isolated from the electric organ of Torpedo.

J Blasi1, G Egea, M J Castiella, M Arribas, C Solsona, P J Richardson, J Marsal.   

Abstract

Torpedo electric organ has been used to study the binding of botulinum neurotoxin type A to pure cholinergic synaptosomes and presynaptic plasma membrane. 125I-labeled botulinum neurotoxin type A exhibits specific binding to cholinergic fractions. Two binding sites have been determined according to data analysis: a high affinity binding site (synaptosomes: Kd = 0.11 +/- 0.03 nM, Bmax = 50 +/- 10 fmol.mg prot-1; presynaptic plasma membrane: Kd = 0.2 +/- 0.05 nM, Bmax = 150 +/- 15 fmol.mg prot-1) and a low affinity binding site (synaptosomes: Kd approximately 26 nM, Bmax approximately 7.5 pmol.mg prot-1; presynaptic plasma membrane: Kd approximately 30 nM, Bmax approximately 52 pmol.mg prot-1). The binding of 125I-botulinum neurotoxin type A is decreased by previous treatment of synaptosomes by neuraminidase and trypsin, and by a preincubation with bovine brain gangliosides or antiserum raised against Torpedo presynaptic plasma membrane. When presynaptic plasma membranes are blotted to nitrocellulose sheet, either 125I-botulinum neurotoxin or botulinum toxin-gold complexes bind to a M(r) approximately 140,000 protein. Botulinum toxin-gold complexes have also been used to study the toxin internalization process into Torpedo synaptosomes. The images fit the three step sequence model in the pathway of botulinum neurotoxin poisoning.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334417     DOI: 10.1007/bf01250791

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  37 in total

1.  Botulinum neurotoxin inhibits the release of newly synthesized acetylcholine from torpedo electric organ synaptosomes.

Authors:  J Marsal; C Solsona; X Rabasseda; J Blasi
Journal:  Neurochem Int       Date:  1988       Impact factor: 3.921

2.  Relationship of acceptors for botulinum neurotoxins (types A and B) in rat CNS with the cholinergic marker, chol-I.

Authors:  D M Evans; P J Richardson; A Fine; W T Mason; J Oliver Dolly
Journal:  Neurochem Int       Date:  1988       Impact factor: 3.921

3.  Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin.

Authors:  N Bakry; Y Kamata; L L Simpson
Journal:  J Pharmacol Exp Ther       Date:  1991-09       Impact factor: 4.030

4.  Sialic acids: metabolism of O-acetyl groups.

Authors:  R Schauer
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

5.  125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord.

Authors:  E Habermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 7.  Clostridial neurotoxins: handling and action at the cellular and molecular level.

Authors:  E Habermann; F Dreyer
Journal:  Curr Top Microbiol Immunol       Date:  1986       Impact factor: 4.291

8.  Continuous determination by a chemiluminescent method of acetylcholine release and compartmentation in Torpedo electric organ synaptosomes.

Authors:  M Israël; B Lesbats
Journal:  J Neurochem       Date:  1981-12       Impact factor: 5.372

9.  Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis.

Authors:  J D Black; J O Dolly
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

10.  Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.

Authors:  J D Black; J O Dolly
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.